Clinical Trial Update: Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects [Phase 3]

View source ↗

Summary

This is a Phase 3 long-term safety extension study update for the olanzapine/samidorphan combination (OLZ/SAM) in pediatric subjects with bipolar I disorder or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• OLZ/SAM (olanzapine/samidorphan)

Snippet

Sponsor: Alkermes, Inc. | Conditions: Bipolar I Disorder, Schizophrenia | Phase 3 | Status: ENROLLING_BY_INVITATION